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In vivo and in vitro biotransformation of the lithium salt
of gammamlinolenic acid by three human carcinomas
R de Antueno, M Elliot, G Ells, P Quiroga, K Jenkins and D Horrobin
Scotia Research Institute, PO Box 818, Kentville, NS, Canada, B4N 4H8
Summary Lipid metabolism has been considered recently as a novel target for cancertherapy. In this field, lithium gamma-linolenate (LiGLA)
is a promising experimental compound for use in the treatment of human tumours. In. vivo and in vitro studies allowed us to assess the
metabolism of radiolabelled LiGLA by tumour tissue and different organs of the host. In vitro studies demonstrated that human pancreatic
(AsPC-1), prostatic (PC-3) and mammary carcinoma (ZR-75-1) cells were capable of elongating GLA from LiGLA to dihomo-gamma-linolenic
acid (DGLA) and further desaturating it to arachidonic acid (AA). AsPC-1 cells showed the lowest A5-desaturase activity on DGLA. In the in
vivo studies, nude mice bearing the human carcinomas were given Li[1-14C]GLA (2.5 mg kg-') by intravenous injection for 30 min. Mice were
either sacrificed after infusion or left for up to 96 h recovery before sacrifice. In general, the organs showed a maximum uptake of radioactivity
30 min after the infusion started (t= 0). Thereafter, in major organs the percentage of injected radioactivity per g of tissue declined below 1%
96 h after infusion. In kidney, brain, testes/ovaries and all three tumour tissues, labelling remained constant throughout the experiment. The
ratio of radioactivity in liver to tumour tissues ranged between 16- and 24-fold at t = 0 and between 3.1- and 3.7-fold at 96 h. All tissues
showed a progressive increase in the proportion of radioactivity associated with AA with a concomitant decrease in radiolabelled GLA as the
time after infusion increased. DGLA declined rapidly in liver and plasma, but at a much slower rate in brain and malignanttissue. Seventy-two
hours after the infusion, GLA was only detected in plasma and tumour tissue. The sum of GLA + DGLA varied among tumour tissues, but it
remained 2-4 times higher than in liver and plasma. In brain, DGLA is the major contributor to the sum of these fatty acids. Data showed that
cytotoxic GLA and DGLA, the latter provided either by the host or by endogenous synthesis, remained in human tumours for at least 4 days.
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INTRODUCTION
Gamma-linolenic acid (GLA; 18:3n-6) and dihomo-gamma-
linolenic acid (DGLA 20:3n 6)' both with three double bonds in the
cis configuration, have been shown to have a wide range of anti-
cancer and/or antiproliferative effects (Horrobin, 1994; Jiang et al,
1995). These n-6 fatty acids are derived from linolenic acid
(18:2fn6) and can be converted to arachidonic acid (AA; 20:4fn 6)' as
shown in Figure 1.
Co-culture experiments in which normal and malignant cells
were cultured together in the same dish demonstrated that cancer
cells were selectively responsive to GLA and its elongation
product, DGLA, when added to the culture medium at concentra-
tions that do not harm normal cells (Begin et al, 1986). In contrast,
arachidonic acid, the A5 desaturation product of DGLA, exhibits
cytotoxic effects on cancer cells but is not as selective as its
precursors (Begin, 1987).
One possible mechanism of action is based on the fact that these
n-6 fatty acids can bypass the A6-desaturase deficiency reported in
some malignant cells and/or restore towards normal thelow levels of
polyunsaturated fatty acids detected in certain cancer patients (van
Hoeven and Emmelot 1973; Feraon et al, 1996). On exposure to
GLA the cancer cells generate higher levels of superoxide
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radicals, lipid peroxidation products and/or eiscosanoids, many of
which compounds have anti-tumour properties (Sakai and
Yamaguchi, 1984; Das et al, 1987; Takeda et al, 1992).
Furthermore, GLA seems to have the ability to induce apoptosis
(de Kock et al, 1994) and to inhibit arange ofmechanisms respon-
sible for metastasis. Indeed, GLA has now been shown to restore
defective E-cadherin function in human lung, colon, breast,
melanoma and liver cancer cells, with a corresponding loss of
invasiveness (Jiang et al, 1995). GLA or its metabolites were
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Figure 1 GLA elongation and desaturation pathways. Abbreviations: GLA,
gamma-linolenic acid (18:3,>6); DGLA, dihomo-gamma-linolenic acid (20:3, 6);
AA, arachidonic acid (20:4,,6); 22:3,r6, direct elongation product of DGLA;
ADA, adrenic acid (22:4,,6)
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effective in inhibiting enzymes associated with metastasis or
closely correlated with metastatic potential such as urokinase (du
Toit et al, 1994), 12-lipoxygenase (Honn et al, 1994; Ziboh, 1996)
and 5-lipoxygenase (Ziboh, 1996). In addition, GLA inhibits
cell-matrix interactions and so GLA exerts inhibitory effects at
several stages in the multistep process of tumour formation and
progression (Jiang et al, 1996).
Particularly promising therapeutic effects were obtained with
the administration of GLA directly into the tumour cavity in
patients with malignant glioblastomas and astrocytomas (Das et al,
1995). The tumours regressed and survival was substantially
prolonged. The inhibitory effect ofGLA on the growth ofa human
lung mucoepidermoid carcinoma, breast cancer and malignant
melanoma (de Bravo et al, 1994; Pritchard et al, 1989) was also
observed in immunodeficient animal models.
In most of these studies GLA was either administered orally in
the form of triglyceride, ester or free fatty acid or injected intra-
venously in the form of the relatively water-soluble lithium salt
(Fearon et al, 1996). Potassium salts were not considered because
of potentially adverse cardiac effects. The lithium salt had an
advantage over the sodium salt in that the rate ofinfusion could be
monitored by measuring the lithium blood concentrations with
routine hospital analytical techniques. Toxicity of lithium is not a
concern if the serum levels of lithium remain below those
commonly used in chronic psychiatric treatments (Fearon et al,
1996). A phase II1 dose escalation study in patients with inoper-
able pancreatic cancer showed that the higher doses of LiGLA
were associated with longer survival times without an important
adverse outcome and, in particular, without the serious effects
commonly related with chemotherapy (Fearon et al, 1996).
As unsaturated lipids are now serious candidates for novel anti-
cancer drugs, it is important to understand the metabolism of
LiGLA in cancerpatients. We have therefore examined the in vivo
and in vitro uptake, elongation and further desaturation of radio-
labelled LiGLA by three human carcinomas.
MATERIALS AND METHODS
Animals and human carcinomas
Seven-week-old athymic CD1BR (nu/nu) mice were obtained
from Charles River Canada (St Constant, Quebec, Canada) and
housed in polycarbonate cages with air filter tops in a pathogen
temperature-controlled environment (25 ± 1°C) with a 12-h
light/dark cycle. Animals weremaintained adlibitum on agamma-
irradiated chow diet and sterile water (pH 2.5). Mouse manipula-
tions were performed in a class II laminar flow hood.
ZR-75-1, PC-3 and AsPC-1 (human mammary, prostatic and
pancreatic carcinomas respectively; American Type Culture
Collection, Rockville, MD, USA) were grown in Dulbecco's
modification of Eagle medium [DMEM; containing 10% fetal
bovine serum (FBS), penicillin (50 IU ml-') and streptomycin
(50 jg ml-')] in a humidified atmosphere of 95% air and 5%
carbon dioxide at 37°C. Cell culture media and supplements were
obtained from ICN Biomedicals, Costa Mesa, CA, USA.
In vitro experiments
At 90% confluency, malignant cells were incubated in fresh
medium with either the free acid form or the lithium salt of
[1-'4C]GLA (sp. act. 58 mCi mmol-'; New England Nuclear,
Boston, MA, USA). Radiolabelled GLA or LiGLA was diluted
with unlabelled fatty acids (Nu-CheckPrep, Elysian, MN, USA) to
give a final specific activity of 6.06 mCi mmol-'. Ethanolic fatty
acid solutions were added directly to six-well dishes to give a final
concentration of 66 gM and 0.1% for fatty acids and ethanol
respectively (total radioactivity 1 gCi in 2.5 ml). Three days after
the addition of fatty acids, the cell monolayer was washed three
times with phosphate-buffered saline (PBS) and the cells were
harvested in PBS using a rubber policeman. The cell suspension
was kept in the freezer (-20°C) until lipid extraction.
In vivo experiments
All cell lines were suspended in their growth medium and a
solubilized attachment matrix, Matrigel (1/1 v/v; Collaborative
Research, Bedford, MA, USA). Male mice were injected s.c. into
the interscapular region with 300 jil of the suspension containing
5 x 106 of either AsPC-1 or PC-3 cells, whereas female mice
were injected with the same amount ofZR-75-1 cells.
When tumours became palpable, they were measured twice
weekly with digital slide calipers (FV Fowler, Newton, MA, USA)
connected to a computerized system. Tumour volume was calcu-
lated for an ellipsoid by the formula V= 1 x w x h/2, where 1 is the
length, w is the width and h is the height, in millimetres.
Li[1-14C]GLA administration
In the in vivo experiments conditions were designed to mimic, as
much as is possible in an animal model, the infusion protocol
followed with cancerpatients (Fearon et al, 1996).
At approximately 300 mm3 tumour volume animals were anaes-
thetized with sodium pentobarbital (80 mg kg-'; Somnotol, MTC
Pharmaceuticals, Cambridge, Ontario, Canada). Mice were then
given 125 jil of 0.9% sodium chloride with 200 IU kg-' heparin
and 14 ,uCi of Li[1-'4C]GLA (more than 98% radiochemical
purity; 58gCi jimol-1; New England Nuclear) by slow intravenous
injection through the tail vein (2.53 mg kg-' over 30 min) using a
paediatric 27 G butterfly and infusion pump.
Mice were sacrificed either immediately after the 30 min
infusion (time 0) or left for recovery for either 24, 48 or 96 h until
sacrifice by exsanguination under halothane anaesthesia.
Organs were perfused (via the heart left ventricle, vena cava and
portal vein) and rinsed with cold 0.9% sodium chloride and blotted
dry. Aliquots of each tissue were solubilized with Solvable 0.5 M
(New England Nuclear) at 56°C.
In order to reduce chemiluminescence, samples were decol-
orized with hydrogen peroxide and neutralized with glacial acetic
acid before adding the cocktail (Formula 989, New England
Nuclear) for scintillation counting.
Lipid analysis
Lipids from malignant cell suspensions and from organ and
tumour tissues were extracted with chloroform-methanol (2:1,
v/v) (Folch et al, 1957). The total lipid extract was methylated
using boron fluoride in methanol at 90°C for 30 min (Morrison
and Smith, 1964). The resultant radiolabelled fatty acid methyl
esters (FAMEs) were analysed as previously described (de
Antueno et al, 1994). Analyses were carried out on a Waters
Associates (Milford, MA, USA) high-performance liquid chro-
matograph equipped with a variable wavelength UV-VIS monitor
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Figure 2 Growth rate of ZR-75-1, AsPC-1 and PC-3 (human mammary,
pancreatic and prostatic carcinomas respectively) in athymic nude mice.
Animals were injected with malignant cells suspended in a 1:1 (v/v) solution
of their growing medium and Matrigel. Tumour volume was measured with
digital calipers and calculated for an ellipsoid by the formula V= /x wx h/2,
where /is the length, wis the width and hthe height in millimeters. Values
are the means ± s.d. from at least five mice
(set at 205 nm), a radioisotope detector (model 171, Beckman,
Fullerton, CA, USA) with a solid scintillator cartridge (97% effi-
ciency for 14C detection) and with either an ultrasphere ODS
column 250 mm x 4.6 mm ID (5 gm particle size, Beckman) or
with a Symmetry ODS column 150 mm x 3.9 mm ID (5 gm
particle size, Waters). FAMEs were separated isocratically with
acetonitrile-water (95:5, v/v) at a flow rate ofeither 1 ml min- or
0.5 ml min-' for the 250- and 150-mm columns respectively and
were identified by comparison with authentic standards. Under
these experimental conditions the resolution and retention times of
FAMEs were identical in both columns.
RESULTS
In vivo experiments
Tumour data
Tumour take of 100% and latency periods of 6-8 days (the time
between the injection and a palpable tumour size) were found for
all three cell lines (AsPC-1, ZR-75-1 and PC-3) suspended in the
solubilized basement membrane extract, Matrigel (Figure 2). The
volume doubling times (VDTs), calculated in the exponential
growth phase between 200 and 400 mm3 (Boven, 1991), were 8,
10 and 16 days for AsPC-1, ZR-75-1 and PC-3 respectively.
ZR-75-1 and PC-3 tumours showed a longer lag phase than the
pancreatic carcinoma.
Radiolabelled fattyacid uptake
Figure 3 shows the radioactivity recovered in different tissues
expressed as per cent of injected dose per gram of tissue at 0
and 96 h after the slow intravenous infusion for 30 min of
Li[l-14C]GLA. Similar results were obtained from AsPC-l, PC-3
and ZR-75-1 tumour tissues.
There were considerable variations in the radioactivity per
tissue weight among the different organs. The initial radiolabelled
recoveries per gram (or ml) in different tissues ranked (highest to
lowest) as follows: liver, urine, lung, kidneys, heart, spleen,
ovaries, pancreas, plasma, brain, tumour, testes, fat and red cells.
In general, the organs showed a maximum uptake ofradioactivity
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Figure 3 Tissue distribution, as per cent of injected dose g-' tissue, at 0 and
96 h post-injection for Li[1-14C]GLA. Nude mice bearing either human
pancreatic (AsPC-1), prostatic (PC-3) or mammary (ZR-75-1) carcinomas
received an intravenous infusion of 14 pCi of Li[l-14C]GLA for 30 min. * and
V denote values obtained at time 0 and 96 h afterthe slow infusion
respectively. RBC, red blood cells. Values are the means ± s.d. of at least
four mice
at time 0 (30 min after the infusion started). Thereafter, in major
organs the percentage of injected radioactivity per gram of tissue
declined below 1% at 96 h following infusion. The average
radioactivity in fat tissue increased twofold at 96 h in AsPC-1
host mice, whereas in kidneys, brain, testes/ovaries and all
three tumour tissues labelling remained approximately constant
throughout the experiment. The ratio of radioactivity in liver to
that in the three tumour tissues was 16-, 24- and 28-fold at time 0
and 3.1-, 3.6- and 3.7- fold at 96 h after the infusion of AsPC-1,
PC-3 and ZR-75-1 host mice respectively.
GLA metabolites
Liver, brain and tumour tissue were examined for the presence of
radiolabelled elongation and A5 desaturation products of GLA
(Figure 4). Data from plasma were also included. Liver and brain
were selected as they provided enough material for the HPLC
analysis and because they are potential sites for the development
ofmetastatic malignant tumours.
An unidentified radiolabelled compound that may be22:3fn6, the
direct elongation product of DGLA, was not included in the
figures. The levels of this fatty acid did not exceed 3-4% of total
radioactivity recovered at early time points in host livers and
plasma whereas, in tumour tissue, those concentrations were only
detected within 24-96 h after infusion.
All tissues showed a progressive increase in the proportion of
radioactivity associated with AA with a concomitant decrease in
radiolabelled GLA as the time after infusion increased. DGLA
levels declined rapidly in liver and plasma but at a much slower
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Figure 4 Per cent distribution of radioactivity among GLA metabolites in total lipids of host liver, plasma, brain, AsPC-1, P0-3 and ZR-75-1 carcinomas as a
function of the post-infusion time. Nude mice bearing human tumours received an intravenous infusion of 14 ,uCi of Li['4C]GLA for 30 min Radiolabelled fatty
acids are denoted as follows: 0, GLA, gamma-linolenic acid (18:3,.,6);E*, DGLA, dihomo-gamma-linolenic acid (20:3,,6); *, AA, arachidonic acid (20:4,,6). An
unknown fatty acid (presumably 22:3T6) with concentrations below 4% is not included in the graphs. The shaded areas represent the sum of radiolabelled GLA
and DGLA percentages. Values are the means s.d. of at least four mice
Table 1 [14C]GLA + ['4C]DGLA/[14C]AA ratios in total lipids of host liver,
plasma, brain and human carcinomas as a function of the post-infusion time
of Li[14C] GLA
Time Tumour Liver Plasma Brain
(h)
AsPC-1 PC-3 ZR-75-1
0 3.68 2.24 1.82 1.65 2.32 0.96
24 1.36 1.21 NA 0.41 0.70 0.54
48 1.13 0.80 NA 0.17 0.44 0.37
96 0.84 0.18 0.10 0.11 0.00 0.33
AsPC-1, PC-3, ZR-75-1: human pancreatic, prostatic and mammary
carcinomas respectively. NA, not available
rate in brain and malignant tissue. Seventy-two hours after the
infusion, GLA was detected only in plasma and tumour tissue. At
this time point the sum of GLA + DGLA varied among tumour
tissues, but it remained two (in PC-3) to four times (in AsPC-1)
higherthan that found in liverandplasma. Inbrain, DGLA was the
major contributor to the sum ofthese fatty acids.
At 96 h after the infusion, the fatty acid composition of host
liver, brain and plasma was similar in the mice carrying all three
cancers (data not shown).
When all these data were calculated in terms of microgram per
gram of tissue, the findings were also consistent with those based
on the percentage data. Forexample, forAsPC-1 host mice at 48 h,
the liver contents of DGLA and AA were 0.35 and 2.99 ,ug g-'
respectively, whereas in the pancreatic carcinoma the levels of
GLA, DGLA and AA were 0.06, 0.16 and 0.20 ,ug g-' respectively.
This represents a concentration ofabout 0.42 jig oftotal n-6 PUFAs
produced from Li[l-l4C]GLA per ml of tumour tissue, assuming
unit density ofmalignant tissue (Houchens and Ovejera, 1991).
Table 1 shows that tumour (in particular AsPC-1 and PC-3) and
brain tissues maintained higher ratios of GLA+DGLA/AA than
plasma and liver tissue for 48-96 h after infusion. Differences
were observed among tumours but, by 96 h after infusion, the ratio
slowly decreased 4 and 12 times in AsPC-1 and PC-3 respectively,
whereas in liver the ratio declined 15-fold. ZR-75-1 tumours
showed exceptionally lower ratios, similar to those found in liver.
In brain tissue the ratio changed more slowly.
In vitro experiments
The in vitro incubations with radiolabelled GLA or LiGLA were
performed for 72 h as the concentrations of GLA and DGLA in
tumours grown in nude mice were relatively slow-changing with a
concomitant increase of AA within 48-72 h after the infusion of
LiGLA. Also, at this time point cells were 90% viable as deter-
mined by a routine Trypan Blue exclusion test. These results are
consistent with those reported previously in which evidence of
extensive cell death was not detected until day 6 (Begin et al,
1986; Begin and Ells, 1987).
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Figure 5 Per cent distribution of radioactivity among GLA metabolites in total
lipids of AsPC-1, PC-3 and ZR-75-1 carcinoma cells. Radiolabelled GLA
solutions were added directly to six-well dishes to give a final concentration of
66,UM. Cells were harvested 72 h after the addition of GLA to the medium.
Radiolabelled fatty acids are denoted as follows:*, GLA, gamma-linolenic
acid (18:3r6); Z, DGLA, dihomo-gamma-linolenic acid (20:3,6); E, AA,
arachidonic acid (20:4, 6); 1, (22:3,J6); m, ADA, adrenic acid (22:4,,J). tr,
trace amount; nd, non-detectable. Values are the means ± s.d. of at least
three separate dishes
There were no significant differences in the metabolism ofGLA
when it was provided either in the form of free acid or lithium salt
to cells grown in vitro. Thus, the graphs presented in this study
were generated from either GLA or LiGLA experiments.
Figure 5 shows the capability of AsPC-l, PC-3 and ZR-75-1
cells to produce DGLA, AA and the elongation products ofboth -
22:3n6 and 22:4fn6 respectively - when GLA was provided in the
medium. Significant differences were observed in the distribution
of radioactivity among n-6 fatty acids in different carcinomas. At
72 h of incubation, ZR-75-1 cells produced the highest levels of
AA with similar concentrations of GLA and DGLA. In contrast,
AsPC-1 cells showed the highest levels of DGLA and the lowest
concentrations of AA, whereas in PC-3 intermediate values were
detected. These differences were reflected in the GLA+DGLA/AA
ratios shown in each panel ofFigure 5.
DISCUSSION
The nude mouse model allowed us to examine in three distinct
human carcinomas (with different growth rates, Figure 2, and
grown in male or female mice), the uptake (Figure 3) and biocon-
version ofGLA (Figure 4) intravenously administered in the form
of the lithium salt. In this model, when malignant cells were co-
injected in the presence of a membrane basement matrix
(Matrigel), tumours grew well, maintaining their histopathological
characteristics (data not shown). By using this technique tumour
sizes and shapes were homogeneous and predictable and, in partic-
ular, the mammary carcinoma (ZR-75-1) cells did not require the
normally used pretreatment with P-oestradiol (Osborne, 1985).
Thus, effects due to supraphysiological hormonal concentrations
in female mice and effects of exogenous hormones on the activity
of A5-desaturase were avoided (Brenner, 1990).
The different origins and biological characteristics of the carci-
nomas grown either in vivo or in vitro could be correlated with
some differences in their metabolism of GLA. However, in the in
vivo time course study similar levels of total radiolabelled fatty
acids were found (Figure 3). Relatively high concentrations of
GLA and DGLA were found in all these tumours 72 h after LiGLA
administration. There were no substantial differences in the GLA
metabolism in host liver, plasma and brain of mice bearing either
pancreatic, prostatic or mammary carcinomas (Figures 3 and 4).
These findings support and expand similar results from in vivo
studies with a human ovarian carcinoma and host nude mouse
tissues reported previously (de Antueno et al, 1996).
The Li[1-'4C]GLA dose (2.5 mg kg-' for 30 min) was similar to
that used in pancreatic cancer patients (Fearon et al, 1996). Under
these experimental conditions concentrations of about 0.4 jg ml'
of n-6 fatty acids derived from radiolabelled GLA were reached in
tumour tissue at 48-72 h after infusion. If these values are extra-
polated to a dose that would be administered during a 24 h infusion
(120 mg kg-') they might eventually be within the range of cyto-
toxic concentrations (5-50,ug ml-') for malignant cells according
to in vitro studies (Begin et al, 1985). Total radioactivity per gram
of tissue did not vary for at least 96 h in tumour, brain, fat and
testes/ovaries whereas in other host tissues labelling declined
substantially (Figure 2). Thus repeat dosing may lead to a cumula-
tive increase in concentration. A similar trend to accumulate these
n-6 fatty acids may occur in humans as the results from experi-
ments in which deuterated DGLA was administered to volunteers
indicated that DGLA could be stored in brain and liver and
remained in plasma (El Bustani et al, 1986). In the present study,
the concentrations of DGLA produced from radiolabelled GLA in
brain tissue were practically constant for 4 days. This indicated
that either GLA was incorporated from the plasma and further
elongated or that DGLA was taken up directly from the plasma.
The permeability of the blood-brain barrier for the highly
lipophilic GLA and DGLA could be helpful in chemotherapy with
n-6 fatty acids for tumours localized in the brain.
The higher initial amount (16- to 28-fold) of radiolabelled n-6
fatty acids taken up by the liver compared with that recovered in
tumours may reflect differences in the vascularization of the liver
and subcutaneously grown carcinomas and also differences in liver
metabolism offatty acids. This accumulation may be helpful in the
management of liver metastasis. Subcutaneously transplanted
tumours proliferate more rapidly than their blood supply (Morton
et al, 1982). This may partially explain the slower decay of
radioactivity in tumour tissue relative to the liver within the 96-h
period ofthe present experiment, although this explanation cannot
account for the similar slow decay in brain and testes/ovaries,
which may be related to the high lipid contents of these organs.
Similar differences between malignant and normal tissue uptake
after 1 h ofintravenous infusion ofn-6 fatty acids were reported in
early studies using tissues of the same origin, rat hepatoma and
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host rat liver (DeTomas and Mercuri, 1977). This suggests that
once the n-6 fatty acids were taken up and further metabolized by
the tumour they were retained for a longer period of time than in
the liver. Our findings with slow infusions of LiGLA are consis-
tent with previous studies (Hassam and Crawford, 1978) in which
almost one-half of the radioactivity recovered from the liver
and plasma lipid fractions, 22 h after oral administration of
['4C]DGLA, was still present as DGLA, probably because of its
slower 3-oxidation than that shown by GLA.
Extrapolations from in vitro to in vivo experiments must be
made with caution. The pathways for showing how GLA was
metabolized by human carcinomas in the experimental conditions
of this study are presented in Figure 1. The in vitro experiments
demonstrated that pancreatic (AsPC-1), prostatic (PC-3) and
mammary carcinoma (ZR-75-1) cells are all capable of incorpo-
rating GLA and producing DGLA and AA by the elongation and
A5 desaturation systems (Figure 5). AA was elongated to adrenic
acid (22:4f_6) in very small amounts (Figure 5). The low A5-
desaturase activity detected in AsPC-1 and PC-3 carcinomas is
common in malignant cells (Morton et al, 1979). This low enzy-
matic activity may be partially attributed to the fact that these cell
lines are from humans in which the A5 desaturase activity is low
compared with other species (El Bustani et al, 1986). However,
substantial A5-desaturase activity was detected in ZR-75-1 cells
(Figure 5) and in other human hepatoma cells (Marra and Alaniz,
1992). The metabolic pathways for n-6 fatty acids were also
demonstrated in a human lung mucoepidermoid carcinoma grown
in immunodeficient mice (de Antueno et al, 1988).
In this study GLA, apart from being metabolized to DGLA and
AA, was also available for incorporation as GLA into tissue lipids.
However, the presence of GLA metabolites in tumour tissue does
not necessarily reflect the ability ofthese tumours grown in vivo to
elongate and further A5 desaturate GLA. These metabolites could
have been taken up selectively by the tumours from the host
plasma. The DGLA and AA levels detected in tumours grown in
mice were to some degree related to those detected in vitro for
each tumour tissue. However, the total percentage of AA in the in
vivo studies was higher than that in the in vitro studies (Figures 4
and 5). It has been proposed elsewhere (Voss and Sprecher, 1988)
that AA produced in liver can be transported and used for
membrane synthesis in cells and tissues that do not have an
adequate capacity to make sufficient AA from n-6 fatty acid
precursors. However, it is likely that the altered radiolabelled fatty
acid composition mirrors changes in the metabolic pathways ofthe
tumours (DeTomas and Mercuri, 1977; Morton et al, 1982).
In summary, these in vivo and in vitro experiments demon-
strated that the elongation and A5 desaturation systems remained
active in these human tissues after malignant transformation. The
in vivo study showed that LiGLA was well tolerated by host mice
and led to increases in GLA and DGLA in many tissues. The
prolonged half-life (retention time) of these n-6 fatty acids in
PC-3, AsPC-1 and ZR-75-1 human carcinomas compared with
other major organs ofthe mouse may be important in therapy.
ABBREVIATIONS
GLA, gamma-linolenic acid (A6,9,12-octadecatrienoic acid);
DGLA, dihomo-gamma-linolenic acid (A8,11,14-eicosatrienoic
acid); AA, arachidonic acid (A5,8,11,14-eicosatetraenoic acid);
ADA, adrenic acid (A7,10,13,16-docosatetraenoic acid); LiGLA,
lithium gamma-linolenate; sp. act., specific activity.
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